Please provide your email address to receive an email when new articles are posted on . Having a chronic respiratory infection in addition to bronchiectasis heightened the risk for an exacerbation and ...

Please provide your email address to receive an email when new articles are posted on . HONOLULU — Patients with non-cystic fibrosis bronchiectasis and persistent Aspergillus fumigatus faced a ...

Brensocatib is the first approved therapy for non–cystic fibrosis bronchiectasis and the first dipeptidyl peptidase 1 inhibitor for neutrophil-mediated diseases. The ASPEN trial showed brensocatib ...

Trajectory of patient outcomes for those diagnosed with bronchiectasis is explored by Dr Metersky. This is a video synopsis/summary of an Insights involving Mark Metersky, MD, FCCP, on the prognosis ...

Mucoactive agents did little to stave off pulmonary exacerbations of non-cystic fibrosis bronchiectasis, the CLEAR trial showed. In the two-by-two factorial trial testing hypertonic saline and ...

Results of a large, global clinical trial spanning five continents with over 1,700 patients with bronchiectasis has demonstrated benefits of an investigational, once-a-day pill called brenso catib as ...

Bronchiectasis is a long-term lung condition where the airways stay widened and inflamed. These airway changes make it harder to breathe and clear mucus. People with bronchiectasis live with a ...

Bronchiectasis is defined as a permanent and abnormal dilation of the bronchi due to destruction of the bronchial wall. The thoracoscopic approach is represented in the literature by a few reports, ...

MPR: What is non-cystic fibrosis bronchiectasis? Dr Addrizzo-Harris: Non-cystic fibrosis bronchiectasis is an abnormality of the airways in the lung where the airways become dilated, often permanently ...

Boehringer Ingelheim has breathed life into an American Lung Association campaign, providing support for a new push to educate people with bronchiectasis about how to better manage the disease.

Non-Cystic Fibrosis Bronchiectasis Treatment Market to Reach USD 3.5 Bn by 2035 at 5.8% CAGR, Driven by rising disease burden ...